Veradermics, Inc (MANE) Stock Price & Analysis
Veradermics, Inc (MANE) rose 6.19% to USD 95.91 as of June 10, 2026 at 11:05 UTC, according to Nexqual real-time market data.
MANE last closed at USD 90.32; the session ranged USD 91.77–97.19 on volume of 446,044 shares. Market capitalization is $4.01B, with a 52-week range of USD 32–117.71 (NYQ). Source: Nexqual, June 10, 2026 at 11:05 UTC.
Key Statistics (as of June 10, 2026 at 11:05 UTC)
| Price | USD 95.91 |
|---|---|
| Change | ▲ 6.19% (up) |
| Previous Close | USD 90.32 |
| Open | USD 91.33 |
| Day Range | USD 91.77 – 97.19 |
| 52-Week Range | USD 32 – 117.71 |
| Volume | 446,044 shares |
| Market Cap | $4.01B |
| Exchange | NYQ |
Technical Analysis (MANE)
Nexqual's technical model rates MANE "BUY" based on 5 bullish and 2 bearish signals across 86 daily candles, as of June 10, 2026 at 11:05 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 46.42 (neutral) |
| vs SMA50 | Above (USD 88.57) |
| MACD | 0.98 (positive) |
Analyst Ratings (MANE)
Wall Street analysts rate MANE "Strong Buy" based on 4 analysts, with a mean price target of USD 132.25 (range USD 120–138), per Nexqual as of June 10, 2026 at 11:05 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 132.25 |
| High Target | USD 138 |
| Low Target | USD 120 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (MANE)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.67 |
| Revenue Estimate | $0 |
Source: Nexqual, June 10, 2026 at 11:05 UTC.
Financials & Fundamentals (MANE)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 0 |
| Current Ratio | 59.12 |
| Total Cash | $390.80M |
| Total Debt | $0 |
Source: Nexqual, June 10, 2026 at 11:05 UTC.
Financial Health Score (MANE)
Nexqual rates Veradermics, Inc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 11:05 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $391M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$79M |
| Efficiency | Mixed — No data |
Ownership (MANE)
| Insider Ownership | +2.74% |
|---|---|
| Institutional Ownership | +79.44% |
| Shares Outstanding | 41.78M |
| Float | 27.21M |
| Short % of Float | +8.69% |
Source: Nexqual, June 10, 2026 at 11:05 UTC.
Leadership (MANE)
Veradermics, Inc is led by Reid Waldman (age 30), CEO & Director, per Nexqual as of June 10, 2026 at 11:05 UTC.
| CEO & Director | Reid Waldman (age 30) |
|---|---|
| CFO & Treasurer | Dominic Carrano (age 39) |
| Senior Director of Manufacturing Sciences & Technology | Karl Pruss |
| Vice President of Development & Scientific Operations | Michael Smolinski (age 47) |
| Vice President of Clinical Development & Regulatory Affairs | Aron Shapiro (age 47) |
Major Backers & Investors (MANE)
Notable institutional backers of Veradermics, Inc include Suvretta Capital Management, LLC, SR One Capital Management, LP, Citadel, according to Nexqual as of June 10, 2026 at 11:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Suvretta Capital Management, LLC | 9.98% |
| SR One Capital Management, LP | 5.75% |
| Citadel | 4.37% |
| FMR, LLC | 4.29% |
| Viking Global | 4.05% |
| Siren, L.L.C. | 3.6% |
| JPMorgan | 3.48% |
| abrdn Healthcare Opportunities Fund | 2.93% |
Source: Nexqual, June 10, 2026 at 11:05 UTC.
From Veradermics, Inc's Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Our proprietary research indicates that 93% of patients would like to address their PHL yet only 9% are satisfied with their current treatment.
- In our proprietary market surveys of Americans with PHL, survey respondents cited more rapid onset of growth as a primary desire in a treatment for PHL.
- Our proprietary market research identified that the second most common reason that current OTC users are not using a prescription product is lack of awareness of prescription offerings.
Partnerships
- If VDPHL01 is approved as the first oral therapy for women, we believe it could be especially well-received among the approximately 30 million female PHL patients in the United States. 8 n Evaluate strategic collaboration to maximize the value of our product candidates and deliver meaningful benefits to patients.
- We may selectively consider strategic collaboration opportunities to expand the reach and maximize the value of VDPHL01. n Identify additional solutions to pervasive unmet needs in dermatology.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 66.93 | ▲ 11.29% |
| SYRE | Spyre Therapeutics, Inc. | USD 76.44 | ▲ 3.79% |
| EIKN | Eikon Therapeutics, Inc. | USD 8.77 | ▼ 2.12% |
| KLRA | Kailera Therapeutics, Inc. | USD 19.64 | ▲ 1.39% |
| EVMN | Evommune, Inc. | USD 20.49 | ▲ 2.86% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 11:05 UTC. This page is informational and not investment advice.